Varicella (Chickenpox)

The natural course of varicella follows a well-characterized timeline from exposure to resolution and subsequent lifelong latency.

Incubation period (10–21 days, typically 14–16 days): Following respiratory or conjunctival exposure, VZV replicates in the nasopharyngeal lymphoid tissue and undergoes a primary viremia at approximately days 4–6, seeding the reticuloendothelial system (liver, spleen). A secondary viremia at days 10–14 disseminates the virus to the skin, causing the characteristic exanthem. The patient is infectious from approximately 1–2 days before rash onset until all lesions have crusted (typically 5–7 days after rash onset).

Day 0 (rash onset): The exanthem begins on the face and scalp, rapidly spreading to the trunk. The first lesions are erythematous macules that quickly evolve to papules and then to the classic thin-walled vesicles on an erythematous base. Fever (38–39°C) and malaise accompany rash onset.

Days 1–4 (active eruption): New crops of lesions appear every 12–24 hours for 3–5 days, creating the pathognomonic picture of lesions at multiple stages simultaneously. Pruritus intensifies as more vesicles develop. Fever persists and peaks during the period of maximum new lesion formation. The total lesion count is highest on the trunk and proximal extremities.

Days 5–7 (crusting phase): New lesion formation ceases. Existing vesicles progressively crust over. Once all lesions have crusted, the patient is no longer considered infectious. Pruritus may persist or even intensify during this phase as healing progresses.

Days 7–14 (resolution): Crusts fall off over 1–2 weeks, revealing pink, slightly depressed areas that gradually normalize. Fever resolves. Energy levels gradually return to baseline. Mild scarring may occur at sites of secondary infection or deep excoriation.

Latency (lifelong): Following primary infection, VZV migrates along sensory nerves to establish permanent latency in dorsal root ganglia and cranial nerve ganglia. The virus persists in a non-replicating state, held in check by T-cell immunity. Waning cellular immunity with age or immunosuppression can lead to viral reactivation and herpes zoster, typically decades later.

In most cases, varicella can be diagnosed clinically based on the characteristic rash and clinical history. However, laboratory confirmation is increasingly important in the vaccine era, as modified or "breakthrough" varicella may present atypically.

Clinical diagnosis is straightforward in classic cases: the combination of a generalized, pruritic vesicular rash with lesions at all stages of development (macules, papules, vesicles, crusts simultaneously), centripetal distribution (trunk > extremities), and a history of exposure within the preceding 10–21 days is highly suggestive. However, in vaccinated individuals, the rash may be atypical — fewer lesions (<50), predominantly maculopapular rather than vesicular, and with mild or absent systemic symptoms — making clinical diagnosis less reliable.

Direct fluorescent antibody (DFA) testing of vesicle scrapings was the former gold standard for rapid VZV identification, providing results within 1–2 hours. DFA has largely been superseded by PCR in many settings but remains useful in point-of-care scenarios.

Polymerase chain reaction (PCR) for VZV DNA is the current gold standard, offering the highest sensitivity (>95%) and specificity (100%). PCR can be performed on vesicle fluid, scrapings, crusts, saliva, blood, or CSF. It can distinguish between wild-type VZV and vaccine strain (Oka), which is critical for surveillance and for evaluating possible vaccine-related adverse events.

Viral culture of vesicle fluid can isolate VZV but is slow (7–14 days), has low sensitivity (30–50% as VZV is labile), and has been replaced by PCR for diagnostic purposes. Culture remains useful for antiviral susceptibility testing in cases of suspected acyclovir resistance.

Serology (VZV IgG and IgM) is useful for assessing immunity rather than acute diagnosis. VZV IgG by ELISA or glycoprotein-based ELISA (gpELISA) determines immune status for healthcare workers, pregnant women, and immunocompromised individuals. IgM serology for acute diagnosis is unreliable due to false positives and cross-reactivity. A 4-fold rise in IgG between acute and convalescent sera confirms recent infection but is retrospective.

Varicella is a globally distributed infection, but its epidemiology varies significantly by climate zone, which has important implications for travelers.

Epidemiological variation by region: In temperate climates, varicella is predominantly a childhood disease with peak incidence at ages 4–10, and adult susceptibility is low (<5%). In tropical and subtropical regions, however, the age of infection is shifted upward, and adult susceptibility rates of 20–50% have been documented in parts of South-East Asia, sub-Saharan Africa, and the Caribbean. This means adult travelers from temperate countries who are non-immune face higher exposure risk in tropical settings, where they may encounter susceptible adults and different transmission dynamics.

Pre-travel assessment:

• All travelers should verify their varicella immunity status before international travel. Evidence of immunity includes: documented 2-dose vaccination, laboratory confirmation of immunity (VZV IgG positive), healthcare provider-diagnosed varicella or herpes zoster, or birth in a country with universal varicella vaccination before 1980 (US-specific criterion).

• Non-immune travelers should receive the 2-dose varicella vaccine series (minimum 4-week interval for ages ≥13) at least 4 weeks before departure to allow for immune response development.

Special populations:

• Pregnant women who are non-immune represent a particularly high-risk travel group. Varicella vaccine is contraindicated in pregnancy. Non-immune pregnant travelers should avoid contact with known varicella or zoster cases and should be aware of post-exposure VariZIG availability.

• Immunocompromised travelers should ensure that household contacts and travel companions are vaccinated against varicella.

Cruise ships and group travel: Varicella outbreaks on cruise ships and in group travel settings (camps, tours) are well documented. The high transmissibility of VZV (R₀ 10–12) means that a single case in a susceptible group can cause a rapid outbreak. Vaccination of susceptible individuals before group travel is the best prevention.

Healthcare access: Travelers who develop varicella abroad should seek medical attention, particularly adults, pregnant women, and immunocompromised individuals. Acyclovir is widely available internationally but may require a prescription. VariZIG availability is limited in many countries.

Varicella is a globally endemic disease with an epidemiology that has been dramatically altered by vaccination in countries with universal programs, while remaining largely unchanged in countries without routine varicella immunization.

Pre-vaccine epidemiology (temperate climates): Varicella was a near-universal childhood infection, with annual incidence approximately matching the birth cohort. In the United States, this translated to approximately 4 million cases annually, with peak incidence at ages 5–9 years. Over 95% of adults had serological evidence of prior infection. The disease showed strong winter-spring seasonality (peak March–May in the Northern Hemisphere). Annual burden included approximately 10,500–13,000 hospitalizations and 100–150 deaths.

Post-vaccine epidemiology (US and similar programs): Following introduction of the 1-dose varicella vaccine in 1995 and transition to a 2-dose schedule in 2006, the US has seen a >90% decline in varicella incidence, a >90% reduction in hospitalizations, and an >85% reduction in deaths. Disease incidence has declined from approximately 15/1,000 population to <1/1,000. Outbreaks still occur, primarily among unvaccinated individuals, but are smaller and shorter in duration. A similar pattern has been observed in Australia, Germany, and other countries with universal programs.

Tropical epidemiology: In tropical regions, varicella demonstrates distinct epidemiological features: later age of acquisition (peak incidence often in adolescence or young adulthood), lower childhood seroprevalence (50–70% by age 15 vs. >90% in temperate zones), less pronounced seasonality (often peaking during cooler, drier months), and consequently higher adult susceptibility. This has implications for the cost-effectiveness of universal childhood vaccination in these settings.

Global variation in vaccine policy: As of 2024, approximately 40 countries have incorporated varicella vaccine into their routine immunization schedules. Vaccine introduction has been slower than for other childhood vaccines, partly due to concerns about shifting disease to older (higher-risk) age groups if coverage is suboptimal ("the varicella paradox"), and partly due to the relatively low mortality in high-income settings. The WHO recommends varicella vaccination only for countries that can achieve and sustain ≥80% coverage.

Herpes zoster epidemiology: Herpes zoster incidence is approximately 3–5 per 1,000 person-years overall, rising to 10–12 per 1,000 person-years in those aged ≥80. In countries with universal varicella vaccination, zoster incidence in adults has not increased as initially feared (and may eventually decrease as vaccinated cohorts age, since the Oka vaccine strain reactivates less frequently than wild-type VZV).

The prognosis of varicella is excellent in immunocompetent children, with the vast majority recovering completely within 1–2 weeks without sequelae. However, prognosis varies significantly across different populations.

In immunocompetent children (ages 1–9): Varicella is a mild, self-limited illness. The pre-vaccine case fatality rate was approximately 1 per 100,000 cases (0.001%). Complications occur in approximately 2–6% of cases, most commonly secondary bacterial skin infections. Scarring from lesions is uncommon with proper care but may occur, particularly with secondary bacterial infection or excoriation.

In adolescents and adults: Disease severity and complication rates increase substantially with age. The pre-vaccine CFR in adults was approximately 30 per 100,000 cases (0.03%), a 30-fold increase compared to children. Varicella pneumonia occurs in approximately 1 in 400 adults (compared to <1 in 10,000 children) and carries a mortality rate of 10–30% if untreated. Adults are more likely to be hospitalized (6–10-fold higher rate than children) and have longer recovery periods.

In pregnant women: Varicella during pregnancy poses risks to both mother and fetus. Maternal varicella pneumonia is more severe during pregnancy, with historical mortality rates of up to 40% (reduced to approximately 10% with acyclovir therapy). Congenital varicella syndrome occurs in 0.4–2% of pregnancies with maternal varicella in the first 20 weeks. Perinatal varicella (maternal rash 5 days before to 2 days after delivery) can cause neonatal varicella with CFR up to 30% without VariZIG and antiviral treatment.

In immunocompromised patients: Varicella can be severe, prolonged, and disseminated, involving the lungs, liver, and CNS. In the pre-antiviral era, mortality in immunocompromised children with varicella reached 7–10%. With prompt IV acyclovir therapy, mortality has decreased to approximately 1%.

Long-term consequence — herpes zoster: Following recovery from varicella, 10–30% of individuals will develop herpes zoster (shingles) during their lifetime, typically after age 50, with risk increasing with advancing age and immunosuppression. Post-herpetic neuralgia affects 10–20% of zoster patients and can cause debilitating chronic pain.